First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC

Phase III Study Being Initiated For Two-Drug Regimen

 
• By Mandy Jackson
  
Collection of CT colonography
Amgen boosted responses to Lumakras in colorectal cancer by adding Vectibix to the KRAS G12C inhibitor • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D